Nasdaq · Healthcare
NEUROCRINE BIOSCIENCES INC (NBIX)
As-reported financials and recent SEC filings for NEUROCRINE BIOSCIENCES INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.86B
Net income
$478.6M
Net margin
16.7%
Diluted EPS
$4.67
ROE
14.7%
P/E (TTM)
25.9×
Market cap
$16.94B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Gross profit | — | — | — | — | — |
| Operating income | $619.1M | $570.5M | $250.9M | $249.0M | $102.5M |
| Net income | $478.6M | $341.3M | $249.7M | $154.5M | $89.6M |
| Diluted EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →42026-06-09
View on EDGAR →42026-06-09
View on EDGAR →42026-06-08
View on EDGAR →1442026-06-05
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on NBIX
Search NEUROCRINE BIOSCIENCES INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.